PGD Recombinant Monoclonal Antibody

1. identified that 6-phosphogluconate dehydrogenase (6PGD) is critically involved in the development of anaplastic thyroid cancer (ATC) resistance to doxorubicin. 6PGD inhibition disrupts metabolic reprogramming in doxorubicin-resistant ATC cells. PMID: 29534964
2. Studies indicate link between the 6-phosphogluconate dehydrogenase, oxidative pentose phosphate pathway (PPP) and lipogenesis through Ru-5-P-dependent inhibition of serine/threonine protein kinase LKB1-AMPK signalling. PMID: 26479318
3. copy number gain of the PGD gene was consistently identified in cervical cancers but not in the normal tissues PMID: 24125036
4. Results show that 6PGD activity is upregulated with increased lysine acetylation in primary leukemia cells from human patients, providing mechanistic insights into 6PGD upregulation in cancer cells. PMID: 25042803
5. Expression of 6PGD positively correlates with advancing stage of lung carcinoma. Knockdown of 6PGD by shRNA potently inhibits c-Met tyrosine phosphorylation. PMID: 23973484
6. Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence PMID: 22677172
7. Data suggest that the affinity of Nox2 for NADPH is increased in the presence of 6PGDH on cell stimulation. PMID: 21444627
8. Hsa-miR-132 and -212 were negatively correlated with PGD in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. PMID: 20675101

Show More

Hide All

HGNC: 8891

OMIM: 172200

KEGG: hsa:5226

STRING: 9606.ENSP00000270776

UniGene: Hs.464071